Physician profile
Edwin Yu
NPI 1134220544
$9,921.18
in general payments reported to CMS, 2019-2025
22 companies · $945 in 2025
The $945 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,039 · 2020: $69.13 · 2021: $339 · 2022: $482 · 2023: $253 · 2024: $795 · 2025: $945.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,992.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,992.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $6,623.64 | 2019 | |
| Novo Nordisk INC | $1,162.74 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $451.07 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $371.36 | 2019-2025 | Verquvo |
| Lilly USA, LLC | $294.87 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Sumitomo Pharma America, INC. | $146.57 | 2024-2025 | Gemtesa |
| Teleflex LLC | $120.58 | 2023 | Urolift |
| Astrazeneca Pharmaceuticals LP | $119.09 | 2022-2025 | Farxiga |
| Corcept Therapeutics | $115.14 | 2025 | Korlym |
| Boehringer Ingelheim Pharmaceuticals, INC. | $66.73 | 2022-2024 | Jardiance |
| Novartis Pharmaceuticals Corporation | $59.55 | 2022-2024 | |
| Oyster Point Pharma, INC. | $47.67 | 2024 | Tyrvaya |
| Glaxosmithkline, LLC. | $46.01 | 2024 | Arexvy |
| Abbott Laboratories | $43.62 | 2022-2024 | Freestyle Libre 3 |
| Kowa Pharmaceuticals America, INC. | $43.35 | 2025 | Zoryve |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $39.14 | 2019 | |
| Almatica Pharma LLC | $36.42 | 2022 | |
| Amgen INC. | $36.17 | 2021-2025 | Repatha |
| Radius Health, INC. | $35.00 | 2019 | |
| Melinta Therapeutics, LLC | $28.35 | 2019 | |
| Dexcom, INC. | $18.89 | 2025 | Dexcom G6 Transmitter |
| Allergan, INC. | $15.22 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edwin Yu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.